RxDoctor Payments Data

Donald Huston, DO

Pulmonary Disease · Glassboro, NJNPI 1316973563

Payments from drug & device makers

$10,034in general payments, 2019–2025

Across 642 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amgen$830
  • Sanofi$496
  • Philips North America LLC$489
  • Regeneron Healthcare Solutions, Inc.$469
  • Mylan Specialty L.p.$454
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$10,013100%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca63$1,038
Amgen55$830
Sanofi35$496
Philips North America LLC30$489
Regeneron Healthcare Solutions, Inc.27$469
Mylan Specialty L.p.34$454
Sunovion Pharmaceuticals Inc.32$440
GSK27$370
Advanced Respiratory, Inc16$358
Novo Nordisk25$357
Novartis16$343
Insmed, Inc.16$327
Lilly USA, LLC19$279
Mallinckrodt Hospital Products Inc.15$229
Bayer11$226
Esperion Therapeutics, Inc.21$222
Boehringer Ingelheim16$213
Pfizer15$212
Johnson & Johnson21$186
Electromed, Inc.9$183
Merck12$167
ANI Pharmaceuticals, Inc.11$161
Grifols USA, LLC9$134
Exact Sciences5$113
Sun Pharmaceutical Industries Inc.6$111
AbbVie8$105
Amarin Pharma, Inc.7$102
Daiichi Sankyo Inc.7$101
Otsuka America Pharmaceutical, Inc.6$100
Kowa Pharmaceuticals America, Inc.6$83
Boston Scientific1$80
Vifor Pharma, Inc.1$78
Sumitomo Pharma America, Inc.5$77
Takeda Pharmaceuticals U.S.A., Inc.4$64
Kerecis Limited1$58
Mallinckrodt Enterprises LLC4$54
Eisai Inc.4$50
Astellas Pharma US Inc3$47
Idorsia Pharmaceuticals US Inc3$45
Circassia Inc.3$43
Nabriva Therapeutics, PLC3$43
Actelion Pharmaceuticals US, Inc.3$39
Scilex Pharmaceuticals Inc.2$38
Abbott2$36
Inspire Medical Systems, Inc.2$36
Axsome Therapeutics, Inc.2$35
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$34
Lundbeck LLC2$32
Teva Pharmaceuticals USA, Inc.2$29
Seqirus USA Inc2$28
Baxter Healthcare1$23
Reprise Biomedical, Inc.1$22
Linus Health, Inc.1$20
Verona Pharma, Inc.1$19
Resmed Corp1$19
Evoke Pharma, Inc.1$18
Ultragenyx Pharmaceutical Inc.1$17
Almatica Pharma LLC1$15
Optinose US, Inc.1$14
Harmony Biosciences LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,034 in reported general payments places this provider in the 80th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$244,822
Medicare patients
634
Services billed
2,787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter207$191,425
EliquisApixaban471$177,423
XifaxanRifaximin37$67,350
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$46,712
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$35,319
EntrestoSacubitril/Valsartan83$29,500
XareltoRivaroxaban83$29,415
FarxigaDapagliflozin Propanediol34$22,557
Incruse ElliptaUmeclidinium Bromide40$19,881
Repatha SureclickEvolocumab12$18,634
JardianceEmpagliflozin23$18,332
JanuviaSitagliptin Phosphate30$16,015
Atorvastatin Calcium1,142$15,974
Icosapent Ethyl25$12,958
Aripiprazole94$12,579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta, Breo Ellipta$370$233,538283 claims
PfizerEliquis$212$177,423471 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$34$67,35037 claims
AstraZenecaBreztri Aerosphere, Farxiga$1,038$57,87667 claims
Boehringer IngelheimJardiance, Combivent Respimat, Glyxambi$213$33,87460 claims
NovartisEntresto$343$29,50083 claims
Johnson & JohnsonXarelto$186$29,41583 claims
MerckJanuvia$167$16,01530 claims
Astellas Pharma US IncMyrbetriq$47$5,27013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Glassboro

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →